Compounds > adenine
Page last updated: 2024-10-16

adenine and Drug Abuse, Intravenous

adenine has been researched along with Drug Abuse, Intravenous in 17 studies

Research Excerpts

ExcerptRelevanceReference
"Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent."2.48Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. ( Naggie, S; Sulkowski, MS, 2012)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.88)18.2507
2000's1 (5.88)29.6817
2010's15 (88.24)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Karim, SS1
Choopanya, K4
Martin, M4
Suntharasamai, P4
Sangkum, U4
Mock, PA4
Leethochawalit, M3
Chiamwongpaet, S3
Kitisin, P1
Natrujirote, P1
Kittimunkong, S3
Chuachoowong, R2
Gvetadze, RJ2
McNicholl, JM3
Paxton, LA2
Curlin, ME2
Hendrix, CW1
Vanichseni, S4
Rosenberg, K1
Zhiliang, H1
Yongfeng, Y1
Hudgens, MG1
Cole, SR1
Miller, WC1
Hoffman, IF1
Latkin, CA1
Strathdee, SA1
Shoptaw, S1
Craig, AP1
Gray, R1
Jansson, J1
Wilson, DP1
Bender, BS1
Chaipung, B1
Pérez-Rivera, AÁ1
Sáez, P1
León, E1
Lozano de León-Naranjo, F1
van Griensven, F1
Paxton, L1
Esser, S1
Haberl, A1
Mulcahy, F1
Gölz, J1
Lazzarin, A1
Teofilo, E1
Vera, J1
Körber, A1
Staszewski, S1
Naggie, S1
Sulkowski, MS1
Cohen, J1
Jaruga, P1
Jaruga, B1
Olczak, A1
Halota, W1
Olinski, R1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PC4PrEP: Integrating Pre-Exposure Prophylaxis (PrEP) Into Primary Care[NCT03617874]22 participants (Actual)Interventional2020-02-28Completed
Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005]Phase 1/Phase 298 participants (Actual)Interventional2018-05-24Completed
Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs: a Feasibility Study[NCT04521920]17 participants (Actual)Interventional2020-11-09Completed
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men[NCT04772469]1,509 participants (Actual)Interventional2021-03-22Completed
HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)[NCT02165202]Phase 2136 participants (Actual)Interventional2014-10-31Completed
Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)[NCT05333679]200 participants (Anticipated)Interventional2022-03-02Recruiting
Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand[NCT00119106]Phase 2/Phase 32,413 participants (Actual)Interventional2005-06-30Completed
PrEP Intervention for People Who Inject Substances and Use Methamphetamine[NCT04523519]Phase 4140 participants (Anticipated)Interventional2021-04-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants Who Demonstrate no or Minimal Opioid Use at 3 Months

Defined as self-reported opioid use in prior month (NCT04521920)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Medication and Telemedicine Follow up6

Number of Participants Who Demonstrate no or Minimal Opioid Use at 6 Months

Defined as self-reported opioid use in prior month. (NCT04521920)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Medication and Telemedicine Follow up5

Number of Participants Who Remain HIV Negative at 3 Months

Measured via negative HIV test. (NCT04521920)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Medication and Telemedicine Follow up8

Number of Participants Who Remain HIV Negative at 6 Months

Measured via negative HIV test. (NCT04521920)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Medication and Telemedicine Follow up3

Persistence in Care at 3 Months

Defined as the number of participants who remain on treatment (MOUD or PrEP). (NCT04521920)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Medication and Telemedicine Follow up13

Persistence in Care at 6 Months

Defined as the number of participants who remain on treatment (MOUD or PrEP). (NCT04521920)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Medication and Telemedicine Follow up12

Number of Participants Experiencing Any Grade 2 or Higher AEs During Injection Phase

Number of participants experiencing any Grade 2 or higher clinical and laboratory AEs to evaluate the safety of the injectable product, TMC278 LA (1200 mg dose administered at Weeks 4, 12, 20, 28, 36 and 44), through 48 weeks after initial injection (at Week 52) in women in SSA and the US. (NCT02165202)
Timeframe: Up to 52 weeks

InterventionParticipants (Count of Participants)
Rilpivirine59
Placebo31

Adherence to Study Drug/Placebo

Mean number of days that participants took study drug based on study drug diaries by study group. (NCT00119106)
Timeframe: Participants were asked about adherence at 3 month visits, up to 6.9 years.

Interventiondays (Mean)
Tenofovir84
Placebo84

Adverse Events

Number of Participants with adverse clinical events in tenofovir and placebo arms (NCT00119106)
Timeframe: Up to 6.9 years

Interventionparticipants (Number)
Tenofovir1098
Placebo1083

HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group

Plasma HIV RNA concentrations. (NCT00119106)
Timeframe: Among people who seroconverted, viral load was measured at month 1, 2, and every 4 months after HIV seroconversion

InterventionCopies/mL (Mean)
Tenofovir929829
Placebo120061

Number of Participants Reporting Injecting and Sharing Needles

"Number of Participants reporting injecting and sharing needles:~Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing." (NCT00119106)
Timeframe: Participants were asked about injecting and needle sharing behaviors at enrollment and every 3 month visit, up to 6.9 years

Interventionparticipants (Number)
Tenofovir58
Placebo59

Number of Participants With Tenofovir-associated Resistance Mutations.

Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups. (NCT00119106)
Timeframe: Specimens collected at the time of HIV seroconversion

InterventionParticipants (Count of Participants)
Tenofovir0
Placebo0

Number Participants Who Reported More Than One Sexual Partner at Baseline

Number of participants (NCT00119106)
Timeframe: At enrolment

InterventionParticipants (Count of Participants)
Tenofovir Group251
Placebo Group271

Rates of HIV Seroconversion

Kaplan Meier survival curve. (NCT00119106)
Timeframe: From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years

InterventionInfections/ 100 person-years (Number)
Tenofovir17
Placebo33

Renal Toxicity

Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities (NCT00119106)
Timeframe: Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years

Interventionparticipants (Number)
Tenofovir3
Placebo3

Reviews

1 review available for adenine and Drug Abuse, Intravenous

ArticleYear
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease

2012

Trials

4 trials available for adenine and Drug Abuse, Intravenous

ArticleYear
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum

2013
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012.
    American journal of public health, 2015, Volume: 105, Issue:6

    Topics: Accidents, Traffic; Adenine; Adult; Anti-HIV Agents; Cause of Death; Double-Blind Method; Drug Overd

2015
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Adenine; Administration, Oral; Adult; AIDS Vaccines; Communicable Disease Control; Double-Blind Meth

2011
Oxidative DNA base damage in lymphocytes of HIV-infected drug users.
    Free radical research, 1999, Volume: 31, Issue:3

    Topics: Adenine; Adolescent; Adult; Chromatin; Cytosine; DNA Damage; Guanine; HIV Infections; Humans; Lympho

1999

Other Studies

12 other studies available for adenine and Drug Abuse, Intravenous

ArticleYear
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
    MMWR. Morbidity and mortality weekly report, 2013, Jun-14, Volume: 62, Issue:23

    Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Deoxycytidine; Emtricita

2013
HIV pre-exposure prophylaxis in injecting drug users.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse,

2013
Preexposure prophylaxis reduces HIV risk in injection-drug users.
    The American journal of nursing, 2013, Volume: 113, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Comorbidity; Deox

2013
HIV antiretroviral prophylaxis for injecting drug users.
    Lancet (London, England), 2013, Sep-07, Volume: 382, Issue:9895

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse,

2013
HIV antiretroviral prophylaxis for injecting drug users.
    Lancet (London, England), 2013, Sep-07, Volume: 382, Issue:9895

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse,

2013
HIV antiretroviral prophylaxis for injecting drug users.
    Lancet (London, England), 2013, Sep-07, Volume: 382, Issue:9895

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse,

2013
HIV antiretroviral prophylaxis for injecting drug users.
    Lancet (London, England), 2013, Sep-07, Volume: 382, Issue:9895

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse,

2013
HIV antiretroviral prophylaxis for injecting drug users - Authors' reply.
    Lancet (London, England), 2013, Sep-07, Volume: 382, Issue:9895

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse,

2013
Prophylactic tenofovir reduced HIV infection in injectable drug users.
    Annals of internal medicine, 2013, Sep-17, Volume: 159, Issue:6

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse,

2013
[HIV infected women with intense bone and muscular pain and general weakness].
    Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29, Issue:4

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combina

2011
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.
    European journal of medical research, 2011, Oct-10, Volume: 16, Issue:10

    Topics: Adenine; Adult; Analgesics, Opioid; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female;

2011
AIDS clinical trials. More woes for novel HIV prevention approach.
    Science (New York, N.Y.), 2005, Mar-18, Volume: 307, Issue:5716

    Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic

2005